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1. INTRODUCTION {#irv12535-sec-0006}
===============

Lower respiratory tract illness (LRTI) is a major cause of morbidity and mortality in children worldwide. Several pathogens are capable of causing LRTIs, including bacteria, viruses, and fungi. Notably, 80% of LRTIs are caused by viruses. Human metapneumovirus (HMPV) and human bocavirus (HBoV) are frequently detected in LRTIs.

HMPV, which was originally isolated in the Netherlands[1](#irv12535-bib-0001){ref-type="ref"} and is closely related to avian metapneumovirus, was the first human disease‐causing pathogen identified in the genus metapneumovirus.[2](#irv12535-bib-0002){ref-type="ref"} HMPV causes various clinical symptoms, such as cough, wheezing, and fever.[2](#irv12535-bib-0002){ref-type="ref"} Young children and the elderly are more susceptible to HMPV infection.[2](#irv12535-bib-0002){ref-type="ref"}, [3](#irv12535-bib-0003){ref-type="ref"} Indeed, HMPV mainly infects children under 5 years of age and causes upper respiratory tract and severe lower respiratory tract infections.[4](#irv12535-bib-0004){ref-type="ref"}, [5](#irv12535-bib-0005){ref-type="ref"}, [6](#irv12535-bib-0006){ref-type="ref"}, [7](#irv12535-bib-0007){ref-type="ref"}, [8](#irv12535-bib-0008){ref-type="ref"} HBoV was discovered in Sweden and classified in the family Parvoviridae,[9](#irv12535-bib-0009){ref-type="ref"} and causes various clinical symptoms, including cough, wheezing, and fever.[2](#irv12535-bib-0002){ref-type="ref"} HBoV infections are largely confined to infants and young children (\<24 months). Globally, the average prevalence of HBoV in respiratory tract samples ranges from 1.0 (CI: 0.0‐2.0) to 56.8% (CI: 46.9‐66.8).[10](#irv12535-bib-0010){ref-type="ref"}

However, information about the epidemiological and clinical characteristics of LRTIs caused by HMPV and HBoV in China is limited, particularly regarding the association of viral load and coinfections with clinical features and disease severity. In this study, we investigated the prevalence of HMPV and HBoV in children with LRTIs over a 2‐year period in Changsha, China. The correlation between viral load and the clinical characteristics of patients with HMPV or HBoV infections was explored.

2. METHODS {#irv12535-sec-0007}
==========

2.1. Patients and specimens {#irv12535-sec-0008}
---------------------------

Children (\<156 months of age) hospitalized for LRTI in the First Affiliated Hospital of Hunan Normal University between April 2011 and March 2013 were enrolled in the study after obtaining informed consent from their parents or guardians. All clinical and demographic data of each patient were obtained. Nasopharyngeal aspirates (NPAs) were collected within 1‐3 days of admission to hospital and placed in 2 mL of virus transport medium (Hanks' balanced salt solution with 200 U/mL penicillin, 200 U/mL streptomycin, 200 U/mL amphotericin B, and 0.125% bovine serum albumin \[BSA\]). Specimens were immediately stored at −80°C and transported on dry ice to the National Institute for Viral Disease Control and Prevention, China CDC, where they were stored at −80°C until further processing. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Hunan Normal University hospital.

2.2. Extraction of nucleic acid {#irv12535-sec-0009}
-------------------------------

Viral nucleic acid was extracted from 200 μL of NPA using a QIAamp MinElute Virus Spin Kit (Qiagen, Germany) according to the manufacturer\'s instructions. This kit enables simultaneous extraction of viral RNA and DNA.

2.3. Real‐time PCR for HBoV and HMPV {#irv12535-sec-0010}
------------------------------------

A One‐Step RT‐PCR Kit (Applied Biosystems, USA) was used to amplify HMPV RNA. Each 20‐μL reaction mixture comprised 10 μL of 2× RT‐PCR buffer, 0.4 μL of forward and reverse primers (20 μM), 0.4 μL of probe (10 μM), 0.8 μL of 25× RT‐PCR reverse transcriptase enzyme, 4 μL of template RNA, and 4 μL of ddH~2~O. The real‐time PCR conditions were 50°C for 30 minutes and 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 30 seconds. TaqMan Universal Master Mix II with UNG (Applied Biosystems) was used to detect HBoV. Each 20‐μL reaction mixture comprised 10 μL of buffer, 0.4 μL of forward and reverse primers (20 μM), 0.4 μL of probe (10 μM), 0.8 μL of 25× RT‐PCR reverse transcriptase enzyme, 4 μL of template RNA, and 2.8 μL of ddH~2~O. The real‐time PCR conditions were 50°C for 2 minutes and 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 30 seconds (Table [1](#irv12535-tbl-0001){ref-type="table-wrap"}). To standardize quantification of HBoV and HMPV, known numbers of DNA or RNA transcripts containing the primer targets were used in 10‐fold serial dilutions (10^0^ to 10^7^ copies/μL). Any amplification detected before 40 cycles was considered positive. Quantification of \>10^0^ copies/μL (10^3^ copies/mL) was considered a positive result. An internal positive control gene (*GAPDH*), positive control, and negative (water) control were included in all reactions.

###### 

Primers and probes used for the real‐time polymerase chain reaction

  Assay^*a*^                                       Target gene^*b*^    Primer/probe sequence (5′ to 3′)^*c*^    Source or reference
  ------------------------------------------------ ------------------- ---------------------------------------- ------------------------------------------
  HRV                                              5′ UTR              HRV1A,AGCCTGCGTGGCTGCCTG                 [38](#irv12535-bib-0038){ref-type="ref"}
  HRV1A2, CCTGCGTGGCGGCCARC                                                                                     
  HRV1B, CCCAAAGTAGTYGGTCCCRTCC                                                                                 
  HRVPb, TCCTCCGGCYCCTGAATG                                                                                     
  RSV                                              M                   RSVF,GGCAAATATGGAAACATACGTGAA            [39](#irv12535-bib-0039){ref-type="ref"}
  RSVR,TCTTTTTCTAGGACATTGTAYTGAACAG                                                                             
  RSVPb,CTGTGTATGTGGAGCCTTCGTGAAGCT                                                                             
  FLUA                                             MP                  FLUAF: GAC CRA TCC TGT CAC CTC TGA C     Internal, unpublished
  FLUAR: AGG GCA TTY TGG ACA AAK CGT CTA                                                                        
  FLUAPb: TGC AGT CCT CGC TCA CTG GGC ACG                                                                       
  FLUB                                             Nucleoprotein       FLUBF: CCCACCRAGCAACAAAGG                Internal, unpublished
  FLUBR: CCTTCCGACATCAGCTTCACT                                                                                  
  FLUBPb: CCCGGAACCCATCCCCGGA                                                                                   
  HMPV                                             F                   HMPVF: CAAGTGTGACATTGCTGAYCTRAA          [39](#irv12535-bib-0039){ref-type="ref"}
  HMPVR: ACTGCCGCACAACATTTAGRAA                                                                                 
  HMPVPb: TGGCYGTYAGCTTCAGTCAATTCAACAGA                                                                         
  HCOV‐NL63                                        Nucleoprotein       HCOV‐NL63F: GACCAAAGCACTGAATAACATTTTCC   [40](#irv12535-bib-0040){ref-type="ref"}
  HCOV‐NL63R: ACCTAATAAGCCTCTTTCTCAACCC                                                                         
  HCOV‐NL63Pb:AACACGCT"T"CCAACGAGGTTTCTTCAACTGAG                                                                
  HCOV‐HKU1                                        Nucleocapsid gene   HCOV‐HKU1F: AGTTCCCATTGCTTTCGGAGTA       [41](#irv12535-bib-0041){ref-type="ref"}
  HCOV‐HKU1R: CCGGCTGTGTCTATACCAATATCC                                                                          
  HCOV‐HKU1Pb: CCCCTTCTGAAGCAA                                                                                  
  HPIV1                                            HN                  PIV1F: AGTTGTCAATGTCTTAATTCGTATCAAT      [39](#irv12535-bib-0039){ref-type="ref"}
  PIV1R: TCGGCACCTAAGTAATTTTGAGTT                                                                               
  PIV1Pb:ATAGGCCAAAGA"T"TGTTGTCGAGACTATTCCAA                                                                    
  HPIV2                                            HN                  PIV2F: GCATTTCCAATCTACAGGACTATGA         [39](#irv12535-bib-0039){ref-type="ref"}
  PIV2R: ACCTCCTGGTATAGCAGTGACTGAAC                                                                             
  PIV2Pb:CCATTTACC"T"AAGTGATGGAATCAATCGCAAA                                                                     
  HPIV3                                            HN                  PIV3F: TGGYTCAATCTCAACAACAAGATTTAAG      [39](#irv12535-bib-0039){ref-type="ref"}
  PIV3R: TACCCGAGAAATATTATTTTGCC                                                                                
  PIV3Pb: CCCRTCTG"T"TGGACCAGGGATATACTACAAA                                                                     
  ADV                                              HEXON               AdvF: GCCCCAGTGGTCTTACATGCACATC          [39](#irv12535-bib-0039){ref-type="ref"}
  AdvR: GCCACGGTGGGGTTTCTAAACTT                                                                                 
  AdvPb: TGCACCAGACCCGGGCTCAGGTACTCCGA                                                                          
  HBOV                                             NS1                 HBOV 1F: CCTATATAAGCTGCTGCACTTCCTG       [42](#irv12535-bib-0042){ref-type="ref"}
  HBOV 1R: AAGCCATAGTAGACTCACCACAAG                                                                             
  HBOV 234F: GCACTTCCGCATYTCGTCAG                                                                               
  HBOV 3R: GTGGATTGAAAGCCATAATTTGA                                                                              
  HBOV 24R: AGCAGAAAAGGCCATAGTGTCA                                                                              
  HBOV Pb: CCAGAGATGTTCACTCGCCG                                                                                 

ADV, human adenovirus; HBOV, human bocavirus 1; HPIV, human parainfluenza virus; HMPV, human metapneumovirus; HCoV, human coronavirus; HRV, human rhinovirus; FLVA, influenza virus A; FLVB, influenza virus B; RSV, respiratory syncytial virus; HN, hemagglutinin‐neuraminidase; UTR, untranslated region.
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2.4. Detection of other viruses {#irv12535-sec-0011}
-------------------------------

Ten other respiratory viruses were screened for by real‐time PCR: human rhinovirus (HRV), adenovirus (ADV), respiratory syncytial virus (RSV), influenza viruses A and B (IFVA and IFVB), parainfluenza viruses 1‐3 (PIV1‐3), and human coronaviruses HCOV‐HKU1 and HCOV‐NL63. The real‐time PCR reagent concentrations and conditions used for the detection of all RNA viruses were identical to those for HMPV, and the concentrations and conditions for ADV were identical to those for HBoV.

2.5. Statistical analysis {#irv12535-sec-0012}
-------------------------

Viral loads were expressed as initial copy numbers per real‐time PCR reaction, and quantitative results were transformed as the log number of viral copies/μL. Continuous variables are expressed as means ± standard deviation (SD) and were compared by independent samples *t* test. Categorical variables are expressed as frequencies or percentages. Comparisons were performed by chi‐squared or Fisher\'s exact test. Analyses were performed using SPSS 16.0 software. Two‐sided *P*‐values \<.05 were considered to indicate statistical significance.

3. RESULTS {#irv12535-sec-0013}
==========

3.1. Patients' characteristics {#irv12535-sec-0014}
------------------------------

In total, we analyzed 1092 samples collected from LRTI patients (age 0‐13 years) during a 2‐year period. The most frequent clinical diagnoses were pneumonia (95.79%), bronchiolitis (0.91%), and bronchitis (3.30%). The male‐to‐female ratio was 1.88:1. The majority (84.2%) of the patients were aged \<3 years. The age of the patients ranged from 1 day to 156 months, with a mean of 20.40 ± 24.60 months.

3.2. Virus identification and epidemiological characteristics {#irv12535-sec-0015}
-------------------------------------------------------------

Pneumonia was diagnosed in 253 HBoV‐positive (96.2%) and 196 HMPV‐positive (98.5%) patients. The mean ages of HBoV‐ and HMPV‐positive children were 17.44 ± 21.64 and 18.76 ± 20.60 months, respectively, the difference was not significant (*P* = .506). The mean hospitalization duration of the 1092 patients was 8.08 ± 3.49 days, and those of HBoV‐ and HMPV‐positive children were 7.93 ± 3.43 and 8.28 ± 3.57 days, respectively, the difference was not significant (*P* = .280). Among patients with acute respiratory tract infection, 63.9% (168/263) of HBoV‐positive patients and 61.8% (123/199) of HMPV‐positive patients were hospitalized during their first year of life.

At least one virus was detected in 83.2% (909/1092) of the patients with LRTIs. Of the 1092 samples tested, RSV was detected in 437 (40.0%), FLVA in 78 (7.1%), FLVB in 15 (1.3%), PIV1 in 37 (3.4%), PIV2 in 61 (5.6%), PIV3 in 337 (30.9%), ADV in 228 (20.8%), HRV in 123 (11.3%), HCOV‐HKU1 in 112 (10.3%), HCOV‐NL63 in 57 (5.2%), HMPV in 199 (18.2%), and HBoV in 263 (24.1%). RSV was the virus most frequently detected in patients with respiratory infections, followed by PIV3, HBoV, ADV, and HMPV.

HBoV was detected in every month from April 2011 to March 2013, while HMPV was detected in every month, except for October 2012 (Figure [1](#irv12535-fig-0001){ref-type="fig"}). HBoV infections peaked in summer (32.2%), followed by spring (24.6%), winter (22.0%), and autumn (17.7%) (*P* = .001), while HMPV infections peaked in winter (28.9%), followed by spring (18.8%), summer (13.9%), and autumn (10.5%) (*P* = .000).

![Season distribution of HBOV and HPMV detection rate during a 2‐year study](IRV-12-279-g001){#irv12535-fig-0001}

3.3. Clinical characteristics of HBoV‐ and HMPV‐positive patients {#irv12535-sec-0016}
-----------------------------------------------------------------

Patients were divided into two groups: those with and without HBoV or HMPV infections (Table [2](#irv12535-tbl-0002){ref-type="table-wrap"}). Cough and fever were the most frequent symptoms in HBoV‐ and HMPV‐positive patients. HBoV‐positive patients had a shorter hospitalization duration than HBoV‐negative patients (*P* = .021). There was no significant difference in the clinical features (cough, fever, tachypnea, cyanosis, O~2~ therapy, and WBC count) between HBoV‐positive and HBoV‐negative patients. HMPV‐positive patients had a higher prevalence of fever than HMPV‐negative patients (*P* = .002), while there was no significant difference in the frequency of other clinical features (cough, fever, tachypnea, cyanosis, O~2~ therapy, WBC, and hospitalization duration) between HMPV‐negative and ‐positive patients.

###### 

Clinical features of HBoV‐ and HMPV‐positive patients

  Clinical Data                                                        HBoV           HMPV                                                 
  -------------------------------------------------------------------- -------------- -------------- ------- -------------- -------------- -------
  Cough[a](#irv12535-note-0003){ref-type="fn"}                         246 (93.5%)    754 (90.9%)    .205    188 (94.5%)    826 (92.5%)    .365
  Fever[a](#irv12535-note-0003){ref-type="fn"}                         191 (72.6%)    588 (70.9%)    .639    161 (80.9%)    653 (73.1%)    .002
  Tachypnea^a^                                                         30 (11.4%)     99 (11.9%)     .913    21 (10.6%)     108 (12.1%)    .627
  Cyanosis[a](#irv12535-note-0003){ref-type="fn"}                      11 (4.1%)      39 (4.7%)      .502    9 (4.5%)       41 (4.6%)      1.000
  O~2~ therapy[a](#irv12535-note-0003){ref-type="fn"}                  38 (15.2%)     137 (16.0%)    1.000   33 (16.6%)     142 (16.0%)    .442
  WBC (×10^9^ cells/L)                                                 10.82 ± 5.75   10.99 ± 6.10   .696    10.69 ± 6.04   10.91 ± 5.44   .610
  mean ± SD[b](#irv12535-note-0004){ref-type="fn"}                     n = 263        n = 829                n = 199        n = 893        
  Hospitalization (mean ± SD)[b](#irv12535-note-0004){ref-type="fn"}   7.93 ± 3.43    8.71 ± 5.16    .021    8.27 ± 3.58    8.58 ± 5.04    .409

Calculated by chi‐squared test or Fisher\'s exact test.

Calculated by independent samples *t* test.
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3.4. Viral load and clinical features {#irv12535-sec-0017}
-------------------------------------

Of the patients, 24.1% (263/1092) were infected with HBoV. The log number of copies of HBoV DNA per μL ranged from 1.00 to 10.11 (median 2.72, mean 3.17 ± 1.80). Of the patients, 18.2% (199/1092) were HMPV‐positive. The log number of copies of HMPV RNA per μL ranged from 1.00 to 8.11 (median 3.21, mean 3.60 ± 1.90).

We assessed the relationship between viral load and various clinical characteristics (age, gender, respiratory rate, temperature, cyanosis, hospitalization, and WBC count) (Table [3](#irv12535-tbl-0003){ref-type="table-wrap"}). The HBoV viral load was significantly higher among children aged \<1 year (*P* = .006); however, the other clinical characteristics were not correlated with HBoV load. HPMV load was not correlated with any of the clinical characteristics.

###### 

Correlations between clinical characteristics and viral load

  Clinical Data                                             HBoV   HMPV                                     
  --------------------------------------------------------- ------ ------------- ------ ----- ------------- ------
  Age[a](#irv12535-note-0005){ref-type="fn"}                                                                
  \<1 y                                                     168    3.40 ± 1.92   .006   99    3.46 ± 1.97   .299
  ≥1 y                                                      95     2.77 ± 1.49          100   3.75 ± 1.81   
  Gender[a](#irv12535-note-0005){ref-type="fn"}                                                             
  Male                                                      184    3.25 ± 1.86   .291   125   3.74 ± 1.95   .174
  Female                                                    79     2.99 ± 1.64          74    3.36 ± 1.78   
  Respiratory rate[a](#irv12535-note-0005){ref-type="fn"}                                                   
  Normal                                                    30     3.66 ± 2.24   .122   21    3.44 ± 1.56   .521
  High                                                      233    3.11 ± 1.73          178   3.65 ± 1.98   
  Temperature[a](#irv12535-note-0005){ref-type="fn"}                                                        
  Normal                                                    72     2.85 ± 1.28   .077   36    3.21 ± 1.63   .161
  Fever                                                     191    3.29 ± 1.94          163   3.70 ± 1.94   
  Cyanosis[a](#irv12535-note-0005){ref-type="fn"}                                                           
  No                                                        252    3.51 ± 2.35   .519   190   3.64 ± 1.91   .148
  Yes                                                       11     3.15 ± 1.77          9     2.71 ± 1.31   
  Hospitalization[a](#irv12535-note-0005){ref-type="fn"}                                                    
  \<7 d                                                     93     3.00 ± 1.54   .269   27    3.62 ± 2.01   .916
  ≥7 d                                                      170    3.26 ± 1.92          78    3.59 ± 1.85   
  WBC[a](#irv12535-note-0005){ref-type="fn"}                                                                
  ≤10 (×10^9^ cells/L)                                      143    3.27 ± 1.80   .325   107   3.77 ± 2.11   .180
  \>10 (×10^9^ cells/L)                                     120    3.05 ± 1.80          92    3.41 ± 1.60   

Calculated by independent samples *t* test.
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3.5. Coinfections with other viruses {#irv12535-sec-0018}
------------------------------------

Of the HBoV‐ and HMPV‐positive patients, 83.7% (220/263) and 85.9% (171/199), respectively, were coinfected with other respiratory viruses. The viruses most frequently detected in coinfections with HBoV were RSV (n = 124), PIV3 (n = 113), ADV (n = 69), and HMPV (n = 52). The viruses most frequently detected in coinfections with HMPV were RSV (n = 86), PIV3 (n = 85), HBoV (n = 52), and ADV (n = 49). HBoV and HMPV mean values of viral load were not significantly different between single infections and coinfections (*P* = .764 and *P* = .082) (Figure [2](#irv12535-fig-0002){ref-type="fig"}). Patients infected with HBoV only were older than those coinfected with HBoV and other respiratory viruses (*P* = .005) (Table [4](#irv12535-tbl-0004){ref-type="table-wrap"}). There were no significant differences in the clinical characteristics of patients infected with HMPV and those coinfected with HMPV and other respiratory viruses (Table [5](#irv12535-tbl-0005){ref-type="table-wrap"}).

![Viral loads of NPAs from patients with or without respiratory coinfections](IRV-12-279-g002){#irv12535-fig-0002}

###### 

Clinical characteristics of patients infected with HBoV only and those coinfected with HBoV and other respiratory viruses

  Clinical Data                                            Single HBoV Infection (n = 43)   HBoV Coinfection (n = 220)   *P*
  -------------------------------------------------------- -------------------------------- ---------------------------- -------
  Males[a](#irv12535-note-0006){ref-type="fn"}             31 (72.1%)                       153 (69.6%)                  .856
  Months ± SD[b](#irv12535-note-0007){ref-type="fn"}       26.05 ± 31.22                    15.89 ± 18.94                .005
  Fever[a](#irv12535-note-0006){ref-type="fn"}             29 (67.4%)                       162 (73.6%)                  .717
  Tachypnea[a](#irv12535-note-0006){ref-type="fn"}         4 (9.3%)                         26 (11.8%)                   .796
  Cyanosis[a](#irv12535-note-0006){ref-type="fn"}          2 (4.7%)                         9 (4.1%)                     1.000
  O~2~ therapy[a](#irv12535-note-0006){ref-type="fn"}      6 (14.0%)                        32 (14.5%)                   .806
  Hospitalization[b](#irv12535-note-0007){ref-type="fn"}   7.67 ± 2.82                      7.96 ± 3.54                  .615
  WBC[b](#irv12535-note-0007){ref-type="fn"}               11.64 ± 6.91                     10.64 ± 5.5                  .301
  Diagnosis[b](#irv12535-note-0007){ref-type="fn"}                                                                       
  Bronchitis                                               3 (7.0%)                         7 (3.2%)                     .213
  Pneumonia                                                40 (93.0%)                       213 (96.8%)                  .213

Calculated by chi‐squared test or Fisher\'s exact test.

Calculated by independent samples *t* test.
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###### 

Clinical characteristics of patients infected with HMPV only and those coinfected with HMPV and other respiratory viruses

  Clinical data                                            Single HMPV (n = 40)   HMPV coinfections (n = 159)   *P*
  -------------------------------------------------------- ---------------------- ----------------------------- -------
  Males[a](#irv12535-note-0008){ref-type="fn"}             28 (70.0%)             97 (61.00%)                   .361
  Months ± S D[b](#irv12535-note-0009){ref-type="fn"}      18.86 ± 24.06          19.00 ± 19.91                 .197
  Fever[a](#irv12535-note-0008){ref-type="fn"}             33 (82.50%)            128 (80.50%)                  1.000
  Tachypnea[a](#irv12535-note-0008){ref-type="fn"}         5 (12.5%)              16 (10.1%)                    .773
  Cyanosis[a](#irv12535-note-0008){ref-type="fn"}          3 (7.5%)               6 (3.2%)                      .388
  O~2~ therapy[a](#irv12535-note-0008){ref-type="fn"}      5 (12.5%)              28 (17.6%)                    .634
  Hospitalization[b](#irv12535-note-0009){ref-type="fn"}   8.15 ± 2.43            8.32 ± 3.81                   .786
  WBC[b](#irv12535-note-0009){ref-type="fn"}               10.94 ± 5.42           10.65 ± 6.18                  .787
  Diagnosis[b](#irv12535-note-0009){ref-type="fn"}                                                              
  Bronchitis                                               1 (2.5%)               2 (5.0%)                      .492
  Pneumonia                                                39 (97.5%)             157 (98.7%)                   .492

Calculated by chi‐squared test or Fisher\'s exact test.

Calculated by independent samples *t* test.
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3.6. Viral load and disease severity {#irv12535-sec-0019}
------------------------------------

According to the British Thoracic Society Guidelines for the Management of Community‐Acquired Pneumonia in Children[11](#irv12535-bib-0011){ref-type="ref"} and the clinical diagnosis, LRTIs were classified as mild to moderate or severe. The mean HBoV and HMPV viral loads did not differ significantly between the two groups (*P* = .053 and *P* = .231) (Figure [3](#irv12535-fig-0003){ref-type="fig"}).

![Viral loads of NPAs from patients with mild‐to‐moderate and severe pneumonia](IRV-12-279-g003){#irv12535-fig-0003}

4. DISCUSSION {#irv12535-sec-0020}
=============

In this study, we used real‐time PCR to explore the etiology and examine the correlations between viral load and the clinical features of pediatric HBoV and HMPV LRTIs in Changsha, China, over two consecutive years. Pneumonia was the most frequent diagnosis in HBoV‐positive patients (96.2%) and HMPV‐positive patients (98.5%) with LRTIs, which is in agreement with previous reports,[12](#irv12535-bib-0012){ref-type="ref"}, [13](#irv12535-bib-0013){ref-type="ref"}, [14](#irv12535-bib-0014){ref-type="ref"}, [15](#irv12535-bib-0015){ref-type="ref"} Calvo reported that HMPV‐positive patients were younger than HBoV‐positive patients; in contrast, the ages of HBoV‐ and HMPV‐positive patients did not differ significantly in our study. HMPV and HBoV frequently resulted in hospitalization,[8](#irv12535-bib-0008){ref-type="ref"}, [16](#irv12535-bib-0016){ref-type="ref"} which has been reflected in our results. There was no difference in the mean hospitalization duration of HBoV‐positive (7.93 ± 3.43 days) and HMPV‐positive (8.28 ± 3.57 days) patients. This is not in agreement with the study by Calvo, in which hospitalization duration was longer in patients with HMPV. However, our data are in line with the findings of Davis.[8](#irv12535-bib-0008){ref-type="ref"} Our findings suggest that more attention should be paid to young children with LRTIs due to the considerable hospitalization duration. In our study, HBoV and HMPV infections were almost completely confined to infants and children; 63.9% (168/263) of HBoV patients and 61.8% (123/199) of HMPV patients were hospitalized during their first year of life, in agreement with the study by Edwards.[17](#irv12535-bib-0017){ref-type="ref"} This is likely due to the weak immunity of children aged \<1 year.

At least one virus was detected in 83.2% (909/1092) of patients with LRTIs. This is higher than previous study (62.34%) in Changsha that used traditional PCR,[18](#irv12535-bib-0018){ref-type="ref"} and lower than that a study in Lanzhou that used real‐time PCR.[6](#irv12535-bib-0006){ref-type="ref"} On the one hand, the high detection rate in our study could be caused by the greater sensitivity of real‐time PCR compared with traditional PCR. On the other hand, it is possible that the detection rate differs geographically. RSV was the most frequently virus detected in patients with respiratory infections, followed by PIV3, HBoV, ADV, and HMPV. Our data support previous reports of RSV, PIV3, HBoV, ADV, and HMPV as the major agents associated with LRTIs among children in a hospital setting.[12](#irv12535-bib-0012){ref-type="ref"}, [19](#irv12535-bib-0019){ref-type="ref"}, [20](#irv12535-bib-0020){ref-type="ref"}, [21](#irv12535-bib-0021){ref-type="ref"}, [22](#irv12535-bib-0022){ref-type="ref"} The HBoV infection rate (24.1%) in the present study is consistent with earlier reports (1.9%‐24.6%[8](#irv12535-bib-0008){ref-type="ref"}, [9](#irv12535-bib-0009){ref-type="ref"}, [16](#irv12535-bib-0016){ref-type="ref"}, [23](#irv12535-bib-0023){ref-type="ref"}, [24](#irv12535-bib-0024){ref-type="ref"}, [25](#irv12535-bib-0025){ref-type="ref"}, [26](#irv12535-bib-0026){ref-type="ref"}), and the incidence of HMPV (18.2%) in patients with respiratory tract infections is similar to that in other regions (1.5%‐18%[2](#irv12535-bib-0002){ref-type="ref"}, [9](#irv12535-bib-0009){ref-type="ref"}, [17](#irv12535-bib-0017){ref-type="ref"}, [23](#irv12535-bib-0023){ref-type="ref"}, [26](#irv12535-bib-0026){ref-type="ref"}, [27](#irv12535-bib-0027){ref-type="ref"}, [28](#irv12535-bib-0028){ref-type="ref"}). Therefore, HMPV and HBoV are major causes of LRTIs worldwide.

The seasonal peaks of HBoV and HMPV infections vary among countries because of differences in climatic and geographic factors. In this study, HBoV activity peaked in summer, in agreement with the report by Jiang.[29](#irv12535-bib-0029){ref-type="ref"} In contrast, detection of HBoV in Lanzhou peaked in December and April,[30](#irv12535-bib-0030){ref-type="ref"} possibly due to the dry, cold weather in Lanzhou and the warm, humid weather in Changsha. HMPV detection peaked in winter, which is in line with previous studies.[2](#irv12535-bib-0002){ref-type="ref"}, [7](#irv12535-bib-0007){ref-type="ref"}, [18](#irv12535-bib-0018){ref-type="ref"}, [31](#irv12535-bib-0031){ref-type="ref"} In contrast, in Hong Kong, HMPV detection peaks in spring/summer.[32](#irv12535-bib-0032){ref-type="ref"} The seasonality of HBoV differed geographically, possibly due to climatic factors.

The most frequent symptoms of HBoV‐ and HMPV‐positive patients were cough and fever, in accordance with previous reports.[6](#irv12535-bib-0006){ref-type="ref"}, [18](#irv12535-bib-0018){ref-type="ref"}, [33](#irv12535-bib-0033){ref-type="ref"} However, Deng reported that in Chongqing, wheezing was the most frequent symptom exhibited by HBoV‐positive patients with severe LRTIs.[16](#irv12535-bib-0016){ref-type="ref"} There was no difference between the HBoV‐ and HMPV‐positive patients in the incidence of fever, tachypnea, cyanosis, O~2~ therapy, or WBC count. The HBoV‐positive patients had a shorter hospitalization duration than HBoV‐negative patients (*P* = .021). In contrast, Deng reported that HBoV‐positive patients had a longer hospitalization duration. The longer hospitalization duration of HBoV‐negative patients in our study may have been caused by the presence of other viruses (such as RSV and PIV3) in many of them. Also, hospitalization duration was significantly associated with age (≤6 months), maternal smoking during pregnancy, and a family history of asthma.[19](#irv12535-bib-0019){ref-type="ref"} A high HMPV viral load contributes to development of fever.[4](#irv12535-bib-0004){ref-type="ref"}, [5](#irv12535-bib-0005){ref-type="ref"} Indeed, HMPV‐positive patients had a higher incidence of fever than HMPV‐negative patients (*P* = .002) in our study.

We assessed the relationship between viral load and clinical features (age, gender, respiratory rate, temperature, cyanosis, hospitalization duration, and WBC count). The only significant association of HBoV‐ or HPMV‐positive patients was a higher viral load in \<1‐year‐old HBoV‐positive patients. This is in agreement with Jiang\'s report that patients with a high viral load were significantly younger.[29](#irv12535-bib-0029){ref-type="ref"} In contrast, the duration of wheezing and hospitalization was longer in children with a high than a low HBoV viral load in the study by Deng,[16](#irv12535-bib-0016){ref-type="ref"} possibly due to inclusion of only patients with severe LRTIs.

HMPV and HBoV coinfections with other viruses are common in children. In this study, 83.7% (220/263) of HBoV‐positive patients and 85.9% (171/199) of HMPV‐positive patients had mixed infections. Both the HBoV (83.7%) and HMPV (85.9%) coinfection rate was higher than reported previously (17%‐75%[13](#irv12535-bib-0013){ref-type="ref"}, [25](#irv12535-bib-0025){ref-type="ref"}, [34](#irv12535-bib-0034){ref-type="ref"} and 81.8%,[34](#irv12535-bib-0034){ref-type="ref"} respectively). Similarly, HMPV and HBoV are frequently present as mixed infections.[19](#irv12535-bib-0019){ref-type="ref"}, [20](#irv12535-bib-0020){ref-type="ref"}, [22](#irv12535-bib-0022){ref-type="ref"} RSV was the virus detected most frequently in coinfections with HBoV and HBoV, as reported previously.[6](#irv12535-bib-0006){ref-type="ref"}, [16](#irv12535-bib-0016){ref-type="ref"} Viral load did not differ significantly between single and mixed HBoV and HMPV infections, in agreement with the study by Neske.[6](#irv12535-bib-0006){ref-type="ref"}, [35](#irv12535-bib-0035){ref-type="ref"} HMPV viral load may be significantly correlated with disease course. In contrast, Jiang reported that coinfections were significantly more frequent among patients with a low than a high viral load. Previous studies[15](#irv12535-bib-0015){ref-type="ref"}, [26](#irv12535-bib-0026){ref-type="ref"} reported no difference in the clinical manifestations of children with single and multiple infections. In our study, patients infected with HBoV only were older (26.05 ± 31.22 months) than those infected with HBoV and other respiratory viruses (15.89 ± 18.94 months) (*P* = .005). Analyzing the correlation between viral load and coinfections is problematic because viral load can change rapidly over the disease course; this might explain the conflicting results among studies. Evaluating the clinical significance of one or more coinfecting viruses is difficult.[34](#irv12535-bib-0034){ref-type="ref"}

Viral load is an important determinant of the severity of LRTIs caused by HBoV and HMPV.[16](#irv12535-bib-0016){ref-type="ref"}, [36](#irv12535-bib-0036){ref-type="ref"}, [37](#irv12535-bib-0037){ref-type="ref"} Our findings indicated that a high viral load was not associated with more severe disease, in agreement with a previous study.[6](#irv12535-bib-0006){ref-type="ref"} However, the effect of viral load on disease severity remains controversial. Of the HBoV‐ and HMPV‐positive patients, 83.7% (220/263) and 85.9% (171/199), respectively, were coinfections, and the coinfecting viruses may have contributed to disease severity. Moreover, because the NPAs were obtained during different disease stages, precise quantification could be difficult. This might also explain the conflicting results among reports.

This study has the following strengths: a considerable duration, large number of patients, and comparison of the most common viruses. Its limitation includes the lack of a control group without clinical evidence of illness. Further studies should compare a symptomatic group with a control group and a symptomatic period with an asymptomatic period.

In summary, we present a prospective study of LRTIs caused by HBoV and HMPV. A further comprehensive and in‐depth study of the role of HBoV and HMPV in LRTIs in China is warranted.
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